Jan. 10, 2025

The U.S. Food and Drug Administration (FDA) seeks public comments on draft guidance it published Jan. 7. Of particular interest to the American College of Radiology® (ACR®) is “Artificial Intelligence (AI)-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations.”

The industry guidance outlines a total product lifecycle (TPLC) approach to risk management of AI device software functions, as well as related documentation to support FDA review. It also provides recommendations relevant to transparency and bias mitigation throughout the TPLC, including within the product’s user interface and labelling.

The ACR Informatics Commission and Data Science Institute® (DSI) leadership are reviewing the guidance. The College’s initiatives related to AI are on the DSI website.

Public comments are due to the FDA by April 7.

If you have questions or would like more information about ACR AI/digital health policy, contact Michael Peters, ACR Senior Director, Government Affairs.


Related ACR News

  • ACR Advises Changes to Washington State PAD Report

    ACR urged the WA State Health Technology Clinical Committee to not act on the draft report that would limit coverage of endovascular procedures for PAD.

    Read more
  • Take Action: Contact Your US Senators to Cosponsor ROOT Act

    Support the ROOT Act—Senate cosponsors needed to fix CMS issues with imaging AUC under PAMA. College member advocacy is key.

    Read more
  • Career Growth Through Volunteer Work

    Dr. Bryant Chang shares how early involvement with his state chapter led to launching a medical student section, mentorship program and a symposium.

    Read more